CLIC-2201 / University of British Columbia, BC Cancer Agency - LARVOL DELTA

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: British Columbia Cancer Agency | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • CD4 • CD8

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: British Columbia Cancer Agency | Initiation date: Jul 2024 ➔ Nov 2024

IO biomarker • Trial initiation date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD4 • CD8